MB-102 CD123 CAR

DB17366InvestigationalCell transplant therapies

MB-102 are autologous T cells genetically modified to express CD123-specific, hinge-optimized CD28-costimulatory chimeric receptor and a truncated human epidermal growth factor receptor.

Mechanism: Pharmacologically active on Interleukin-3 receptor subunit alpha
Curator reviewed
Code names: MB102 · MB-102 CD123 CAR

Resolves to

Targets

P26951IL3RA

What you can answer from here — as of July 08, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

9Clinical trialsPhase, status and sponsor resolved per trial

1+ReferenceStructured and connected to the statements they support

Which drugs share a target with MB-102 CD123 CAR, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account